Research and Development Expenses: Research and development expenses for the fourth quarter of fiscal 2021 were $19.4 million compared to $11.6 million for the same period of fiscal 2020.Cost of Revenues: Cost of revenues for the fourth quarter of fiscal 2021 was $22.5 million compared to $17.6 million for the same period of fiscal 2020.The fourth quarter of fiscal 2020 included a single $9 million order that was shipped and recognized as revenue in the quarter. Revenue: Total revenues were $38.0 million for the fourth quarter of fiscal 2021, compared to $32.4 million for the fourth quarter of fiscal 2020.The fourth quarter of fiscal 2020 included a single $9 million order. Orders: Total orders received for the fourth quarter of fiscal 2021 were $45.2 million, compared to $42.7 million for the same period of fiscal 2020.Cash Position: As of September 30, 2021, the company had $477.9 million in cash, cash equivalents and short-term investments.įISCAL 2021 FOURTH QUARTER FINANCIAL RESULTS.Net Loss: Net loss for fiscal 2021 was $152.1 million, or $3.15 per share, compared to $139.9 million, or $3.57 per share, for fiscal 2020.Selling, General and Administrative Expenses: Selling, general and administrative expenses for fiscal 2021 were $135.9 million compared to $103.3 million for fiscal 2020.Research and Development Expenses: Research and development expenses for fiscal 2021 were $69.1 million compared to $43.0 million for fiscal 2020.Cost of Revenues: Cost of revenues for fiscal 2021 was $80.6 million compared to $61.4 million for fiscal 2020.Revenue: Total revenues for fiscal 2021 were $132.3 million compared to $90.1 million for fiscal 2020.Orders: Total orders received for fiscal 2021 were $159.5 million compared to $116.7 million for fiscal 2020.In data storage, we achieved several technical milestones and are now preparing for early access launch with our 1-micron proof-of-concept chip.” In addition, subject to regulatory approval, we expect to have the first Twist-discovered antibody in the clinic in 2022 and we also signed an agreement to acquire Abveris, which will augment our capabilities by adding animal-based discovery. “In biopharma, as of the end of September 2021, we had 34 partners, 41 active and 32 completed programs, with 35 of those programs having milestone payments and/or royalties associated with them. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “Fiscal 2021 was a transformational year for Twist, as we delivered significant revenue growth by diversifying and expanding our customer base in synbio and NGS, as well as introduced new and innovative products,” said Emily M. ‘I would not have been able to do it without him’: I built a property portfolio with 23 units while we were dating.SOUTH SAN FRANCISCO, Calif.-( BUSINESS WIRE)-Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the fourth quarter and full year fiscal 2021 ended September 30, 2021. Home buyers are backing out of contracts in the Sun Belt, especially in Las Vegas, Phoenix, Tampa and Texasīiden’s $10,000 student-debt cancelation is a game-changer for borrowers’ wallets - but will it help their credit scores? My daughter died from a drug overdose, and two of her kids were raised by their other grandparents. Ian regains hurricane strength as it heads toward South CarolinaĬhina’s central bank gives cities room to lower mortgage ratesĮx-NSA worker charged with trying to sell U.S. Jack Dorsey tried to smooth relationship between Elon Musk, Twitter CEO Parag Agrawal, texts showĮx-PG&E executives to pay $117 million to settle lawsuit over wildfires Trevor Noah leaving ‘The Daily Show’ after 7 years
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |